Orphalan announces FDA approval of Cuvrior for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine Paris, France 2 May 2022 - Orphalan
Orphalan strengthens its management team with two key appointments Paris, France 1 February 2022 - Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan